TagCyx is a research based company based in Tokyo (Japan), founded in March 2007 as a spin out company of RIKEN. TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.
Chief Executive Officer:
| Chizuko Koseki, Ph.D |
Board Members:
| Akiyoshi Kudose (CFO) |
| Susumu Muto (CSO) |
| Maiko Katadae (Non Executive Director) |
| Mikio Kawahara (Non Executive Director) |
| Takayuki Okabuchi (Non Executive Director) |
| Hajime Kurachi (Auditor) |
| Takahiro Kono (Auditor) |
| Yoshiyuki Yamakawa (Auditor) |